RNA Nanostructures for Targeted Immune Response Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for cancer and infectious diseases such as influenza and HIV/AIDS are ineffective and pose safety concerns, necessitating new strategies for vaccine design and adjuvant development.
Innovation Solution
Development of RNA-based compositions, including immunostimulatory RNA-containing compositions and RNA nanoparticle-containing compositions, which utilize chemically modified RNA oligonucleotides and immunostimulatory motifs like CpG oligodeoxyribonucleotides to enhance immune responses, incorporating these into RNA nanostructures that self-assemble into stable shapes like triangles, squares, and pentagons for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccines and adjuvants are used, then immune response is triggered, but effectiveness is low and safety concerns arise
Solution Approach 1:
The patent employs composite RNA nanostructures that integrate multiple functional components including immunostimulatory motifs (CpG sequences), antigen-binding elements, and adjuvant molecules into a single nanoscale platform. This composite approach enables simultaneous antigen presentation and immune activation, resolving the contradiction between effectiveness and safety by coordinating multiple immune-modulating functions in a controlled spatial arrangement.
Solution Approach 2:
The RNA nanostructures incorporate localized immunostimulatory CpG motifs at specific positions within the overall structure, creating zones of concentrated immune activation. This local quality approach allows precise control over where and how immune responses are triggered, improving effectiveness while minimizing off-target safety concerns associated with systemic adjuvant distribution.
2Reliability
If new vaccine strategies are developed, then effectiveness may improve, but device complexity increases
Solution Approach 1:
The complex vaccine functionality is segmented into distinct modular RNA components: structural scaffold regions, immunostimulatory CpG-containing regions, antigen-binding regions, and adjuvant recruitment regions. Each module can be independently designed and optimized, then assembled into the complete nanostructure. This segmentation manages complexity by breaking down the overall vaccine design into manageable functional units.
Solution Approach 2:
The RNA nanostructure platform serves multiple functions simultaneously: it acts as an antigen carrier, adjuvant delivery system, immune cell targeting vehicle, and cytokine induction platform. This multi-functionality reduces overall system complexity by consolidating what would otherwise require multiple separate vaccine components into a single integrated nanoscale entity.
3Stability of the object's composition
If RNA oligonucleotides with chemical modifications are used, then stability and immune response are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent systematically modifies RNA oligonucleotide parameters including sugar modifications (2'-O-methyl, 2'-fluoro), base modifications (locked nucleic acids), and backbone modifications (phosphorothioate linkages). These parameter changes enhance RNA stability against nucleases and improve immunostimulatory activity while maintaining programmable self-assembly properties, thereby managing manufacturing complexity through controlled chemical variation.
Solution Approach 2:
The chemically modified RNA oligonucleotides are designed to self-assemble into the final nanostructure through programmed base pairing and structural motifs. This self-assembly capability eliminates the need for complex post-synthesis assembly steps, allowing the manufacturing process to focus primarily on oligonucleotide synthesis and purification, thereby reducing overall manufacturing complexity despite the chemical modifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These RNA-based compositions induce significant immune responses, including cytokine production and antibody induction, with enhanced stability and targeting capabilities, offering improved safety and efficacy compared to traditional adjuvants and vaccines.
Implementation Method 1
RNA oligonucleotides and immunostimulatory motifs...incorporating these into RNA nanostructures that self-assemble into stable shapes
Data Source
AI summary
The present invention is directed towards an artificial RNA nanostructure comprising multiple external strands of RNA, each external strand comprising about 40-50 nucleotides; one internal strand of RNA comprising more than about 50 nucleotides; the internal strands and external strands assembled to form a triangle nanostructure, a square nanostructure, or a polygon nanostructure and a pRNA three-way junction (3WJ) motif at each vertex of the nanostructure. Such nanostructure can be provided in a composition together with an adjuvant for use in inducing the production of high affinity neutralizing antibodies or inhibitory antibodies, inducing the production of cytokines, inducing an immune response in a subject, or a combination thereof.